Access cutting-edge craniopharyngioma treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Washington Dc location
Access craniopharyngioma specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related craniopharyngioma treatment provided free
Check if you qualify for this craniopharyngioma clinical trial in Washington Dc, DC
No-Cost Study Care
Local to Washington Dc
Convenient for DC residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Sponsor: Nationwide Children's Hospital
Yes, this clinical trial (NCT05286788) has an active research site in Washington Dc, DC that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for craniopharyngioma treatment options in Washington Dc, DC, this clinical trial (NCT05286788) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced craniopharyngioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all craniopharyngioma clinical trials near you to find additional studies recruiting in your area.
See all rheumatoid arthritis clinical trials recruiting in Washington Dc — not just this study.
Browse Rheumatoid Arthritis Trials in Washington Dc →